Motive Partners Raises $2.5 Billion
Motive Partners ("Motive"), a leading specialized private equity firm focused on financial technology, today announced the successful final close of its second flagship fund, Motive Capital Fund 2 (the "Fund"), with total capital commitments of $2.54 billion for the Fund and its affiliated co-investment vehicles.
The Fund employs the same investment strategy executed in Motive Partners' inaugural flagship fund. The Fund focuses on growth and buyout investments in software, investment and information services businesses located in North America and Europe. The Fund has already partnered with ten companies - InvestCloud, Insurify, Wilshire, Trumid, Motive Capital Corp II, CAIS, FNZ, Forge Global, BetaNXT and Backbase.
Commitments to the Fund were secured from a geographically diverse group of investors, including public and private pensions, sovereign wealth funds, foundations, financial institutions, institutional fund managers, family offices and high net worth individuals. Existing investors from the inaugural fund were joined by a significant group of new investors.
Rob Heyvaert, Founder & Managing Partner at Motive Partners, commented: "We are deeply grateful for the support from our existing investors and are delighted to welcome a roster of new partners to the Motive family - thank you for your trust. We will continue to be laser-focused on partnering transformational capital with world-class management teams."
During the fundraising period, Motive continued to invest behind its integrated approach, building out the Motive team to include over 180 Investors, Operators and Innovators.
Bob Brown, Founding Partner & Head of Investor Relations, commented: "We greatly appreciate the support of such an esteemed and diverse group of investors, and we take seriously the responsibility that our investors have bestowed upon us. We continue to invest into our distinct operating capabilities, allowing us to identify attractive investment opportunities and support our portfolio companies in the next stage of their growth."
About Motive Partners
Founded in 2016, Motive Partners is a specialist private equity firm with offices in North America and Europe, focused on backing, building, and buying technology companies that enable the financial economy. At the time of the final closing of the Fund, Motive Partners has over $5.5 billion in regulatory assets under management and has established an integrated team of over 180 Investors, Operators and Innovators. The firm focuses on growth equity and buyout investments in software, investment and information services companies in North America and Europe, serving five primary subsectors: Banking & Payments, Capital Markets, Data & Analytics, Wealth & Investment Management, and Insurance. Motive Partners is a privately held firm majority-owned by its partners, and brings differentiated expertise, connectivity, and capabilities to create long-term value in financial technology companies.
More information on Motive Partners can be found at www.motivepartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005158/en/
Contact information
Media:
Sam Tidswell-Norrish
Managing Director, Motive Partners
+44 (0) 7855910178
sam@motivepartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom